EP1181312A1 - Epitopes cytotoxiques de cellule t de la proteine l1 du papillomavirus et leur application en diagnostic et therapie - Google Patents

Epitopes cytotoxiques de cellule t de la proteine l1 du papillomavirus et leur application en diagnostic et therapie

Info

Publication number
EP1181312A1
EP1181312A1 EP00940295A EP00940295A EP1181312A1 EP 1181312 A1 EP1181312 A1 EP 1181312A1 EP 00940295 A EP00940295 A EP 00940295A EP 00940295 A EP00940295 A EP 00940295A EP 1181312 A1 EP1181312 A1 EP 1181312A1
Authority
EP
European Patent Office
Prior art keywords
cell
cells
compound
cell epitope
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00940295A
Other languages
German (de)
English (en)
Inventor
Ingrid Jochmus
John Nieland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medigene AG
Original Assignee
Medigene AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medigene AG filed Critical Medigene AG
Publication of EP1181312A1 publication Critical patent/EP1181312A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • ICWGNQLFV ICWGNQLFV
  • FYNPDTQRL MHGDTPTLH
  • ETTDLYCY QAEPDRAHYN
  • SMVTSDAQI SMVTSDAQI
  • the genome of the papillomaviruses can be divided into three areas:
  • the first area concerns a non-coding region that contains regulatory elements for the transcription and replication of the virus.
  • the second region so-called E (early) region, contains various protein-coding sections E1-E7, of which, for example, the E6 and E7 proteins are responsible for the transformation of epithelial cells and the E1 protein controls the DNA copy number.
  • the E6 and E7 regions are so-called oncogenes that are also malignant degenerate cells are expressed.
  • the third region also called the L (late) region, contains two protein-coding sections L1 and L2 which code for structural components of the virus capsid.
  • L1 protein is understood to mean the main capsid protein of the papillomaviruses (Baker T. et al. (1991) Biophys. J. 60, 1445).
  • HPV-16 has been linked to cervical cancer (cervical cancer).
  • HPV-16 is the main risk factor for the formation of cervical neoplasia.
  • the immune system plays an important role in the progression of the disease. Cellular immune responses and, in particular, antigen-specific T lymphocytes are probably important for the defense mechanism. It was also found that in highly malignant cervical intra-epithelial neoplasia (CIN II / III) and cervical tumors, the E7 gene is constitutively expressed in all layers of the infected epithelium. Therefore, the E7 protein in particular is regarded as a potential tumor antigen and as a target molecule for activated T cells (see e.g. WO 93/20844). However, the E7-induced cellular immune response in the patient does not appear to be strong enough to influence the course of the disease. The immune response may be boosted by appropriate vaccines.
  • capsomers are understood to be an oligomeric configuration that is made up of five Ll proteins.
  • the capsomer is the basic building block from which viral capsids are built.
  • Stable capsomers are capsomers that are unable to form capsids.
  • Capsids are the shell of the papillomavirus, which is composed, for example, of 72 capsomers (Baker T et al (1991) Biophys J 60, 1445)
  • VLP is a capsid which morphologically and in its antigenicity resembles an intact virus.
  • the VLPs were able to trigger a humoral immune response, which is characterized by the formation of neutralizing antibodies, can be used in various deep systems.
  • the formation of virus-neutralizing antibodies against L1 and / or L2 proteins is of less clinical importance, however, if the virus infection has already occurred, since virus is responsible for the infection -fected cells, not antibodies, but a virus-specific cytotoxic T-cell (CTL) response seems to be necessary.
  • CTL virus-specific cytotoxic T-cell
  • a vaccine consisting of CVLPs prevents the pseudoinfection of the
  • CVLPs Underlying cells by the CVLPs This means that the CVLPs enter the cell like viruses, where they are processed into peptides, the peptides are then processed on MHC Class I and II molecules are loaded and ultimately presented with CD8 or CD4 positive T cells.
  • CD8 cells can differentiate into cytotoxic T cells and then cause a cellular immune response
  • CD4 cells develop to T helper cells and stimulate B cells to a humoral or CD8-positive T cells to a cytotoxic immune response and can even induce the lysis of infected cells
  • Presentation in the sense of the present invention means when a peptide or protein fragment binds to an MHC molecule, whereby this binding can take place, for example, in the endoplasmic reticulum, in the extracellular space, the endosomes, proendosomes, lysosomes or protysosomes, and when this MHC-molecule-peptide complex is then bound to the extracellular side of the cell membrane, so that it is bound by immune cells can be specifically recognized
  • CVLPs Since CVLPs trigger both a cellular and humoral immune response and are not MHC-resisting, this technology is generally suitable for the development of vaccines in that the ability to form particles is provided by an Ll component and an additional antigen component in this Ll Share is merged
  • a functional test system that can be used to directly test the immunogenicity of CVLPs.
  • Such a test system should have the property that CVLPs with different antigen contents can be examined with the same test system. Since the cellular immune response is of crucial importance for immunological therapy methods of tumors or viral diseases, the task was to make the cellular immune response caused by CVLPs measurable.
  • T cell epitopes which, in conjunction with MHC molecules, in a special embodiment with HLA A2.01 MHC molecules, trigger a cytotoxic T cell response in vivo and in vitro, for example.
  • These peptides preferably have the sequence ILVPKVSGL, RLVWACVGV, HLFNRAGTV, YLRREQMFV, TLQANKSEV, ILEDWNFGL, SLWLPSEATVYL, NLASSNYFPT, TLTADVMTYI, YLPPVPVSKV, YDLWDQDQF, ICDLQDQHQ, YDLWDQDQF.
  • sequences are part of the Ll and E7 peptides of HPV16.
  • Ll 86-94 amino acid ranges Ll 86-94 (5104), Ll 123-131 (5106), Ll 285-293 (5107), Ll 275-283 (5108), Ll 238-246 (5109), Ll 426-434 (5112 ), Ll 28-39 (2016).
  • the names of the respective epitopes are given in brackets.
  • ILVPKVSGL Under a functionally active variant of ILVPKVSGL, RLVWACVGV, HLFNRAGTV, YLRREQMFV, TLQANKSEV, ILEDWNFGL,
  • SLWLPSEATVYL, NLASSNYFPT, TLTADVMTYI, YLPPVPVSKV, YDLQFIFQL, ICWGNQLFV, FYNPDTQRL, MHGDTPTLH, ETTDLYCY, QAEPDRAHYN or SMVTSDAQizit see for example a T-System-Ep ) one, on the cytotoxicity of ILVPKVSGL, RLVWACVGV, HLFNRAGTV, YLRREQMFV, TLQANKSEV, ILEDWNFGL, SLWLPSEATVYL, NLASSNYFPT, TLTADVMTYI, YLPPVPVSKV, YDLQFIFQL, ICWGNQLFV, FYNPDTQRL, MHGDTPTLH, ETTDLYCY, QAEPDRAHYN or SMVTSDAQI measured cytotoxicity has the minde- least the sum from the mean of the negative controls and three times Standard deviation corresponds, preferably of at least approximately 30%,
  • Such epitopes can be found by counteracting the T cell epitopes ILVPKVSGL, RLVWACVGV, HLFNRAGTV, YLRREQMFV, TLQANKSEV, ILEDWNFGL,
  • non-cytotoxic T cells are also known which can also recognize MHC I molecules, so that non-cytotoxic T cell epitopes are also included as a variant of the present invention.
  • Another embodiment of the present invention is a T cell epitope that is part of a compound, the compound being not a naturally occurring Ll protein of a papilloma virus and not an exclusively N-terminal or exclusively C-terminal deletion mutant of a naturally occurring Ll protein of a papilloma virus .
  • the T cell epitope mentioned as part of a compound can be a polypeptide which preferably contains further amino acid sequences, in particular a fusion protein.
  • the compound can be a polypeptide of at least approximately 50 amino acids, preferably of at least approximately 35 amino acids, in particular of at least approximately 20 amino acids, and in a particularly preferred manner of at least approximately 9-12 amino acids in length.
  • the compound In order to detect the compound or to modify its binding activity to T cells, it can contain a chemical, radioactive isotope, non-radioactive isotope, and / or fluorescent label of the T cell epitope and / or of the fusion protein mentioned.
  • chemical substances known to the person skilled in the art which are suitable for a chemical labeling according to the invention are: biotin, FITC (fluorescein isothiocyanate) or streptavidin.
  • isotopes known to the person skilled in the art which are suitable for radioactive isotope labeling according to the invention are: ⁇ , 1 J, 131 I, 32 P, 33 P or
  • fluorescent substances known to the person skilled in the art which are suitable for a fluorescent label according to the invention are: ⁇ u, fluorescein isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, o-phaldehyde or fluorescamine.
  • Polypeptides according to the invention with an amino acid length of approximately 50 can be produced, for example, by chemical peptide synthesis. Longer polypeptides are preferably genetically engineered.
  • Another object of the present invention is therefore a nucleic acid construct for the expression of said T cell epitope or of the compounds, which contains the following components: (a) at least one regulatory element and (b) at least one nucleic acid which is necessary for an amino acid sequence of encoded connection according to the invention.
  • Said nucleic acid construct is preferably made of DNA or RNA.
  • Suitable regulatory elements allow, for example, the constitutive, regulatable, tissue-specific, cell cycle-specific or metabolically specific expression in eukaryotic cells or the constitutive, metabolically specific or regulatable expression in prokaryotic cells.
  • Regulable elements according to the present invention are promoters, activator sequences, enhancers, silencers, and or repressor sequences.
  • controllable elements which enable cell cycle-specific expression in eukaryotes are the promoters of the following genes: cdc25C, cyclin A, cyclin E, cdc2, E2F, B-myb or DHFR (Zwicker J. and Müller R. (1997) Trends Genet 13, 3-6).
  • Another object of the present invention is a cell that contains at least one T cell epitope, preferably presented.
  • the cell is transfected by one of the vectors mentioned, transformed or infected This cell expresses the polypeptide according to the invention under conditions known to the person skilled in the art which lead to the activation of the regulatable elements used in each case.
  • polypeptide can then be isolated from this cell and, for example, purified using one of the abovementioned labels for genetic engineering production and subsequent purification of the exposed compounds according to the invention are suitable for prokaryotic and eukaryotic cells, in particular bacterial cells such as E co, yeast cells such as S cerevisiae, insect cells such as Spodoptera frugiperda cells (Sf-9) or T ⁇ choplusia ni cells or sucker cells such as for example COS cells or HeLa cells
  • bacterial cells such as E co
  • yeast cells such as S cerevisiae
  • insect cells such as Spodoptera frugiperda cells (Sf-9) or T ⁇ choplusia ni cells
  • sucker cells such as for example COS cells or HeLa cells
  • the compound containing a T-cell epitope can be part of a complex which is characterized in that the compound is covalent or via hydrophobic interactions, ionic bonding or hydrogen bonding is connected to at least one further species such as peptides, proteins, peptoids, linear or branched oligo- or polysaccharides and nucleic acids.
  • the present invention therefore relates to a complex containing a T cell epitope or a compound and at least one further compound.
  • a preferred embodiment is that the polypeptide is present in connection with MHC class I molecules, preferably as HLA A2.01 tetramer. Human MHC class I molecules are particularly preferred.
  • HLA A2.01 tetramers can be prepared with the corresponding bound peptides, which are able to bind to the T cell receptors of peptide-specific cytotoxic T cells.
  • a further embodiment is the immobilization of the compound according to the invention or of the complex mentioned on support materials.
  • Suitable carrier materials are, for example, ceramic, metal, in particular noble metal, glasses, plastics, crystalline materials or thin layers of the carrier, in particular the materials mentioned, or (bio) molecular filaments such as cellulose or framework proteins.
  • a component of the complex can additionally contain a protein tag.
  • Protein tags according to the invention allow, for example, high affinity absorption to a matrix, stringent washing with suitable buffers without eluting the complex to any appreciable extent, and subsequent targeted elution of the absorbed complex.
  • Examples of protein tags known to the person skilled in the art are a (HIS) 6 tag, a Myc tag, a FLAG tag, a hemaglutenin tag, glutathione transferase (GST) tag, intein with an affinity chitin binding Tag or maltose binding protein (MBP) Tag
  • the protein tags according to the invention can be N-, C-terminal, and / or internal
  • Another object of the present invention is a method for in vitro detection of the activation of T cells by at least one compound containing a T cell epitope.
  • Such a method preferably consists of three steps a) In a first step, cells with at least of a compound containing a T-cell epitope stimulated
  • This compound can contain at least one compound according to the invention containing a T-cell epitope, at least one complex according to the invention containing a T-cell epitope, at least one capsomer, at least one stable capsomer, at least one VLP,
  • immune cells are stimulated by incubation with CVLPs.
  • Immune cells stimulated in this way are, for example, after a Vaccination or in a tumor patient nten obtained from the blood, from tumors or from lymph nodes, and / or cultured b)
  • T cells The activation of T cells is determined in a third step.
  • Methods suitable for this include, for example, the detection of the production or secretion of cytokines by the T cells, the expression of sion of surface molecules on T cells, the lysis of target cells or the proliferation of cells. Suitable methods for this are, for example, a cytokine assay (Chapter 6.2 to 6.24 in Current Protocols in Immunology (1999), edited by Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM and Strober W., John Wiley & Sons), ELISPOT
  • the binding of MHC-polypeptide complexes according to the invention to the surface of the T cells is detected.
  • This can be carried out in such a way that the MHC complexes themselves are labeled, for example fluorescence-labeled, or that in a further step an MHC-specific, labeled, for example fluorescence-labeled antibody is used in order to in turn detect the MHC complexes.
  • the fluorescence labeling of the T cells can then be measured and evaluated, for example, in a ' Fluorescens Activated Cell Sorter ' (FACS).
  • FACS Fluorescens Activated Cell Sorter '
  • the present invention also relates to a method which contains an additional step a ') which is introduced after step a).
  • the isolated or cultured cells are loaded with at least one target cell with a compound according to the invention containing a T cell epitope, at least one complex according to the invention containing a T cell epitope, at least one capsomer, at least one stable capsomer, at least one VLP, at least one CVLP and or at least one virus, with at least one complex according to the invention containing a T cell epitope, and / or at least one target cell, the one
  • T cell epitope presented co-cultivated for at least about 8 weeks, in particular for at least about 1 week, before step b) follows.
  • Another object of the present invention is a method for producing a target cell presenting a T cell epitope. It is possible to do this Load target cell with combinations of different T cell epitopes.
  • the target cell is incubated with at least one compound containing a T cell epitope and / or at least one complex containing a T cell epitope.
  • the target cell is incubated in growth medium which contains polypeptides according to the invention or with MHC class I complexes with bound polypeptides according to the invention.
  • the MHC class I complexes can be present, for example, as HLA A2.01 tetramers. A tetramer usually binds four peptides.
  • the target cell is transfected, transformed and / or infected with a nucleic acid and or a vector.
  • the target cell is infected with a vaccinia virus vector.
  • the method according to the invention is carried out with antigen-presenting cells, for example with B cells, macrophages, dendritic cells, embryonic cells or fibroblasts or other HLA A2.01 positive cells, in a preferred embodiment with JY, T2, CaSki cells or EBV cells. transformed B cell lines performed.
  • the CVLPs used contain a Papillomavirus L1 protein or variants thereof, in particular HPV16 L1 protein and, but not necessarily, a protein heterologous to L1 or variants thereof.
  • the two proteins can be bound directly or indirectly.
  • directly bound means that there is a covalent bond between the two proteins, for example a peptide bond or a disulfide bond.
  • Bound indirectly means that the proteins are bound via non-covalent bonds, for example hydrophobic interactions, ionic bonds or hydrogen bonds.
  • the CVLPs contain a papilloma virus L2 protein in addition to Ll protein or variants thereof.
  • the Ll protein can carry one or more mutations or the Ll portion can be composed of Ll proteins from various papillomaviruses his common characteristic of the L1 proteins according to the invention is that they prevent the formation of VLPs or w Allow CVLPs and that they contain at least one T cell epitope according to the invention
  • the L1 protein or variants thereof and the protein heterologous to L1 is a fusion protein.
  • heterologous proteins which are composed of several different proteins or parts thereof.
  • epitopes in particular cytotoxic T- Cell epitopes of proteins being epitopes in the sense of the invention can also be part of a synthetic polypeptide with a length of approx. 50 amino acids, preferably of at least approx. 35 amino acids, in particular of at least approx. 20 amino acids and in a particularly preferred manner of at least approx. 9 amino acids
  • proteins which are heterologous to L1 and which are derived from a viral protein for example derived from HIV, HBV or HCV, preferably from papillomaviruses, in particular from human papillomaviruses
  • this is an E protein of a papilloma virus, preferably an E6 and / or E7 protein.
  • the E protein is a deleted E protein, preferably a C-terminally deleted, in particular a C-terminally deleted E7 protein, since these constructs in connection with deleted L1 protein preferably virus-like particles can train.
  • Deletions of up to 55 amino acids are particularly preferred, preferably approximately 5 to approximately 55 amino acids, in particular approximately 38 to approximately 55 amino acids.
  • the protein heterologous to L1 can be derived from antigens that are not viral pathogens. They can also be derived from autoimmune antigens such as thyroglobulin, myelin basic protein or zona pellucida glycoprotein 3 (ZP 3 ), which are associated with certain autoimmune diseases such as thyroiditis, multiple sclerosis, oophoritis or rheumatoid arthritis.
  • autoimmune antigens such as thyroglobulin, myelin basic protein or zona pellucida glycoprotein 3 (ZP 3 ), which are associated with certain autoimmune diseases such as thyroiditis, multiple sclerosis, oophoritis or rheumatoid arthritis.
  • the protein heterologous to L1 is derived from tumor antigens, preferably melanoma antigens such as MART, ovarian carcinoma antigens such as Her2 new (c-erbB2), BCRA-1 or CA125, colon carcinoma antigens such as CA125 or breast carcinoma antigens such as Her2 new (c- erbB2), BCRA-1, BCRA-2.
  • tumor antigens preferably melanoma antigens such as MART, ovarian carcinoma antigens such as Her2 new (c-erbB2), BCRA-1 or CA125, colon carcinoma antigens such as CA125 or breast carcinoma antigens such as Her2 new (c- erbB2), BCRA-1, BCRA-2.
  • Another object of this invention is a method for the in vitro detection of the activation of T cells, which are obtained by preparation from samples.
  • This method makes it possible to determine whether papillomavirus L1 protein-specific cytotoxic T cells are present in a sample, for example a blood sample from a patient or in tumors or lymph nodes of a tumor patient.
  • a detection method contains the following steps: a ") In a first step, cells are obtained, for example by drawing blood from a patient or by preparing, for example from tumors or lymph nodes. The cells are then taken up in growth medium and cultured. b) In a second step, cells are incubated with at least one target cell which presents a T cell epitope or with at least one complex which comprises as a component a compound containing a T cell epitope.
  • the present invention also relates to a method which contains an additional step a '), which is introduced after step a ").
  • additional step a ' following step a"), the isolated or cultured cells are included at least one target cell loaded with a compound according to the invention containing a T cell epitope, at least one complex according to the invention containing a T cell
  • Cell epitope at least one capsomer, at least one stable capsomer, at least one VLP, at least one CVLP and / or at least one virus, with at least one complex according to the invention containing a T cell epitope, and / or at least one target cell which contains a T Cell epitope presented, co-cultivated for at least about 8 weeks, in particular for at least about 1 week, before step b) follows.
  • Epitope at least one capsomer, at least one stable capsomer, at least one VLP, at least one CVLP, and / or at least one virus, (n) in the presence of at least one complex according to the invention containing a T cell epitope,
  • Another object of the invention is a test system (kit) for the in vitro detection of the activation of T cells containing a) at least one T cell epitope according to the invention, at least one compound according to the invention, at least one vector according to the invention, at least one cell according to the invention, and / or at least one complex according to the invention, and b) effector cells of the immune system, preferably T cells, in particular cytotoxic T cells or T helper cells
  • the test system is used in a special embodiment for determining the L-protein-specific cytotoxic T cells present, for example in a patient's blood sample or in tumors or lymph nodes of a tumor patient.
  • the cells described in b) are contained in the test system Control cells, the activation of which by the first kit component, the substances mentioned under a), serves as standard. The activation observed in this reaction is compared with the T-cell activation of cells isolated from patients by the kit component a)
  • the test system is used, for example, to determine the L1 protein-specific antigenicity of a compound containing a T cell epitope, a complex containing a T cell epitope Capsomers, a stable capsomer, a VLP, a CVLP, and / or a virus.
  • the substances described in a) are control substances whose activating effect on the second kit component, the cells mentioned under b), serves as the standard.
  • Another object of the invention is the use of at least one T cell epitope, at least one compound according to the invention containing a T cell epitope, at least one vector according to the invention containing a nucleic acid coding for a compound containing a T cell epitope, at least one cell according to the invention containing a T cell epitope for, and / or at least one complex according to the invention containing a T cell epitope for triggering or for detecting an immune response.
  • Cells which present at least one of the molecules according to the invention via their MHC class I molecules are particularly suitable for stimulating immune cells in vitro and in vivo.
  • Suitable cells for antigen presentation are e.g. B. B cells, dendritic cells, macrophages, fibroblasts or other HLA A2.01 positive cells, which can stimulate specific T cells by joint cultivation with immune cells.
  • a compound according to the invention for example an HPV18 L1E7 fusion protein, which additionally contains a T cell epitope according to the invention, can be used to detect an immune response.
  • a compound of the invention may have the ability to form CVLPs.
  • Another object of the invention is a medicament or diagnostic agent containing at least one compound according to the invention containing a T cell epitope, at least one vector containing a nucleic acid coding for a compound containing a T cell epitope, at least one cell according to the invention containing a T cell Epitope, and / or at least one complex according to the invention containing a T cell epitope and optionally a pharmaceutically acceptable carrier.
  • the drug or diagnostic agent can be administered in various ways. Examples of administration forms known to the person skilled in the art are parenteral, local and / or systemic administration by, for example.
  • the preferred form of application is influenced, for example, by the natural route of infection of the respective papillomavirus infection.
  • the amount administered depends on the age, weight, general health of the patient and the type of papillomavirus infection.
  • the medicament or diagnostic agent can be administered in the form of capsules, solution, suspension, elixir (for oral administration) or sterile solutions or suspensions (for parenteral or intranasal administration).
  • saline or phosphate-buffered saline can be used as the inert and immunologically acceptable carrier.
  • the drug is administered in therapeutically effective amounts. This means amounts sufficient to elicit a protective immunological response.
  • FIG. 2 shows the graphical evaluation of the fluorescence of T2 cells - measured in a FACS analysis - whose MHC-1 molecules on the cell surface had been labeled by a FITC-labeled antibody.
  • Cell len whose MHC-1 molecules can specifically bind the peptides plotted on the X axis, have increased MHC-1 molecules, since the specific binding stabilizes the MHC complexes so that they can accumulate on the cell surface.
  • FIG. 4 shows the evaluation of FACScan experiments after restimulation of specific human T cells from an HLA AI positive donor with peripheral blood mononuclear cells (PBMC) which present different antigens.
  • PBMC peripheral blood mononuclear cells
  • the name of the respective peptide with which the PBMC was loaded is plotted from left to right. "None” stands for PBMC, which were only incubated with buffer.
  • the proportion of CD8-positive T cells which were classified as reactive on the basis of interferon ⁇ expression in the FACScan experiment is plotted on the Y axis.
  • FIG. 5 shows the evaluation of FACScan experiments after restimulation of specific human T cells from a non-HLA-typed donor with peripheral blood mononuclear cells (PBMC), which present different antigens.
  • PBMC peripheral blood mononuclear cells
  • the name of the respective peptide with which the PBMC was loaded is plotted from left to right. "None” stands for PBMC, which were only incubated with buffer.
  • the proportion of CD4-positive T cells which were classified as reactive on the basis of interferon ⁇ expression in the FACScan experiment is plotted on the Y axis.
  • FIG. 6 shows the evaluation of FACScan experiments after restimulation of specific human T cells from an HLA AI positive donor with peripheral blood mononuclear cells (PBMC) which present different antigens.
  • PBMC peripheral blood mononuclear cells
  • the ratio of the effector cells used to the target cells used is plotted on the X axis, and the% of the specifically lysed target cells, determined by the release of 51 Cr from the target cells, is plotted on the Y axis.
  • The% values were calculated using the formula given in Example 7. Examples
  • T2 cells which can be obtained under the ATCC number: CRL-1992, have a defect in the antigen processing-associated transport which leads to
  • MHC-1 molecules Prevents the loading of MHC-1 molecules in the endoplasmic reticulum.
  • the unloaded MHC-1 molecules still present on the cell surface can be loaded, for example, by incubating the cells in peptide-containing media, so that these cells are very well suited for the presentation of an antigen.
  • PMBC peripheral blood mononuclear cells, the isolation of which is described, for example, in Rudolf MP. et al. (1999), Biol. Chem. 380, 335-40.
  • BLCL means a B cell line transformed with the help of the Epstein-Barr virus (obtained from Dr. Andreas Kaufmann, Friedrich-Schiller-University, Jena, Germany).
  • BB7.2 means an ⁇ -HLA A2.01-specific monoclonal mouse antibody (ATCC HB-82).
  • ⁇ -hum CD28 means a monoclonal mouse antibody which is directed against the extracellular part of human CD28.
  • ⁇ -hum CD3 / PE means a monoclonal mouse antibody that is directed against the extracellular part of human CD3 ( ⁇ ) and contains the fluorescent marker phycoerithrin (Medac, Hamburg, Germany).
  • ⁇ -hum CD4 / Cychrome means a monoclonal mouse antibody which is directed against the extracellular part of human CD4 and which contains the fluorescence marker cychrome (DAKO; Glostrup, Denmark).
  • ⁇ -hum interferon ⁇ / FITC means a monoclonal antibody which is directed against human interferon ⁇ and contains the fluorescent marker FITC (Medac, Hamburg, Germany).
  • ⁇ -hum CD8 / PE means a monoclonal mouse antibody which is directed against the extracellular part of human CD8 and contains the fluorescence marker phycoerithrin (Pharmingen, Heidelberg, Germany).
  • InfluenzaMP means amino acids 58-66 GILGFVFTL of the influenza matrix protein (see Dunbar P.R. et al. (1998) Curr. Biol. 26, 413-6).
  • HPV16E7 peptide means amino acids 11-20 YMLDLQPETT of the human papillomavirus E7 protein.
  • the cells were harvested, washed with PBS containing 0.5% bovine serum albumin (BSA) and the MHC-1 molecules demonstrated. This is done by incubating for 30 min on ice with the BB7.2 antibody, washing and staining with an ⁇ -mouse FITC antibody for a further 30 min on ice. The cells were washed again, measured in a FACScan calibur and analyzed with Cellquest software.
  • BSA bovine serum albumin
  • Human T cells (4x10 " ⁇ ) of an HLA AI positive donor were for 5 weeks with HPV 16L 1 ⁇ C * E7 I _ 55 CVLPs at 37 ° C with weekly addition of 1 ⁇ g / ml CVLPs and 10 5 antigen-presenting cells ( irradiated PMBC) and the cells were then restimulated in 100 ⁇ l medium at 37 ° C. with 10 ⁇ g / ml of the peptides indicated on the X axis of FIG. 4 in the presence of 10 IU / ml IL2 as a negative control served only cells incubated with buffer.
  • FIG. 4 shows that the PBMC incubated with peptides 43, 47 and 48 caused restimulation of CVLP-stimulated T cells, but not the PBMC incubated with the native peptides.
  • Peptide 43 contains the 9mer peptide of the sequence MHGDTPTLH
  • the two overlapping peptides 47 and 48 contain the lOmer peptide of the sequence QAEPDRAHYN, which were described as HLA AI-binding peptides in KITA et al (supra), but for which no functional detection has yet been carried out
  • the T cells of an HLA AI positive donor were then restimulated in 100 ⁇ l medium at 37 ° C. with the peptide pools in the presence of 10 IU / ml IL2.
  • the amounts of the peptide pools used were such that 1 ⁇ g / ml was added for each individual peptide. Only cells incubated with buffer served as a negative control.
  • Target cells which were incubated in medium were used for the spontaneous lysis, target cells which were incubated with 0.5% Triton were used for the maximum lysis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne un épitope de cellule T du papillomavirus avec une séquence d'acides aminés du type ILVPKVSGL, RLVWACVGV, HLFNRAGTV, YLRREQMFV, TLQANKSEV, ILEDWNFGL, SLWLPSEATVYL, NLASSNYFPT, TLTADVMTYI, YLPPVPSKV, YDLQFIFQL, ICWGNQLFV, FYNPDTQRL, MHGDTPTLH, ETTDLYCY, QAEPDRAHYN, SMVTDSDAQI, et/ou une de ses variantes actives, et leur application en diagnostic et thérapie.
EP00940295A 1999-06-01 2000-05-31 Epitopes cytotoxiques de cellule t de la proteine l1 du papillomavirus et leur application en diagnostic et therapie Withdrawn EP1181312A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19925199 1999-06-01
DE19925199A DE19925199A1 (de) 1999-06-01 1999-06-01 Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
PCT/EP2000/005006 WO2000073335A1 (fr) 1999-06-01 2000-05-31 Epitopes cytotoxiques de cellule t de la proteine l1 du papillomavirus et leur application en diagnostic et therapie

Publications (1)

Publication Number Publication Date
EP1181312A1 true EP1181312A1 (fr) 2002-02-27

Family

ID=7909963

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00940295A Withdrawn EP1181312A1 (fr) 1999-06-01 2000-05-31 Epitopes cytotoxiques de cellule t de la proteine l1 du papillomavirus et leur application en diagnostic et therapie

Country Status (7)

Country Link
US (2) US6838084B1 (fr)
EP (1) EP1181312A1 (fr)
JP (1) JP2003502027A (fr)
AU (1) AU5527500A (fr)
CA (1) CA2375802A1 (fr)
DE (1) DE19925199A1 (fr)
WO (1) WO2000073335A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1328287C (zh) * 2005-12-29 2007-07-25 西安交通大学 Hpv16 l1蛋白模拟肽及其用于制备hpv16诊断试剂和疫苗的用途

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL105554A (en) * 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
WO2002004007A2 (fr) * 2000-07-06 2002-01-17 Georgetown University Formes (fixes) stables de proteines virales capsidiales et de proteines virales capsidiales hybrides, de preference les proteines l1 du papillomavirus, et leurs utilisations
DE10059631A1 (de) * 2000-12-01 2002-07-18 Medigene Ag T-Zellepitope des Papillomavirus L1-und E7-Proteins und ihre Verwendung in Diagnostik und Therapie
DE10137102A1 (de) 2001-07-30 2003-02-27 Deutsches Krebsforsch Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung
FR2828934B1 (fr) * 2001-08-27 2004-08-13 Inst Nat Sante Rech Med Test de l'immunite cellulaire par des peptides fixes sur support solide
EP1751300B1 (fr) * 2004-05-11 2017-11-08 AbGenomics Coöperatief U.A. Epitopes induisant la mort des lymphocytes t
EP2012122A1 (fr) 2007-07-06 2009-01-07 Medigene AG Protéines structurelles de parvovirus muté
WO2012031760A1 (fr) 2010-09-08 2012-03-15 Medigene Ag Protéines structurales mutées de parvovirus comprenant des épitopes de cellules b induisant une protection croisée d'une protéine l2 du hpv ainsi que produits et procédés s'y rapportant
CN104274827B (zh) * 2013-07-01 2020-07-14 上海贺普药业股份有限公司 贺普拉肽的制剂

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4777239A (en) 1986-07-10 1988-10-11 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic peptides of human papilloma virus
SE8803870D0 (sv) * 1988-10-28 1988-10-28 Medscand Ab Method for detection of human papillomavirus (hpv) for diagnostic purposes
FR2641081A1 (fr) * 1988-12-23 1990-06-29 Medgenix Group
DE3907721A1 (de) 1989-03-10 1990-09-20 Behringwerke Ag Immunogene regionen auf dem e7-protein des humanen papillomvierus typ 16
CA2038581A1 (fr) * 1990-03-20 1991-09-21 Martin Muller Determinants antigeniques sereux des proteines 16 du virus des papillomes humains (vph)
SE9001705D0 (sv) 1990-05-11 1990-05-11 Medscand Ab Saett foer diagnostik av virusbaerande tumoerer genom immunoassay
WO1992005248A1 (fr) 1990-09-26 1992-04-02 Bristol-Myers Squibb Company Expression de proteines virales du papillome humain et utilisation dans des compositions immunogeniques
WO1992010513A1 (fr) * 1990-12-12 1992-06-25 The University Of Queensland Vaccin a sous-unites contre le virus du papillome et peptides entrant dans sa composition
DE4143467C2 (de) 1991-05-17 1995-02-09 Max Planck Gesellschaft Peptidmotiv und dessen Verwendung
ES2193133T3 (es) 1991-07-13 2003-11-01 Dade Behring Marburg Gmbh Uso de peptidos derivados de los genes e6 y e7 de hpv-16 para fines.
EP1298211B1 (fr) * 1991-07-19 2006-07-12 The University Of Queensland Segment polynucléotidique du génome de l'HPV16
GB9207701D0 (en) 1992-04-08 1992-05-27 Cancer Res Campaign Tech Papillomavirus e7 protein
IL105554A (en) 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
US5662907A (en) 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
US5437951A (en) 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
PT1618888E (pt) 1993-03-09 2011-04-08 Univ Rochester Produção de proteína da cápside de vírus de papiloma humano e partículas semelhantes a vírus
GB2279651A (en) 1993-07-01 1995-01-11 British Tech Group Synthetic peptides of human papillomavirus
GB9313556D0 (en) * 1993-07-01 1993-08-18 British Tech Group Synthetic peptides of human papillomavirus
CA2140591A1 (fr) 1994-01-20 1995-07-21 Josef Endl Lymphocytes t actives, specifiques d'un antigene, detection et utilisation
DE4415743C2 (de) 1994-05-04 1996-10-10 Deutsches Krebsforsch Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
ATE325875T1 (de) 1994-10-07 2006-06-15 Univ Loyola Chicago Papillomavirusähnliche partikel, fusionsproteine sowie verfahren zu deren herstellung
SE9501512D0 (sv) * 1995-04-24 1995-04-24 Euro Diagnostica Ab Synthetic peptide-defined eptopes useful for vaccination against papillomavirus
DE19631357A1 (de) * 1996-08-02 1998-02-05 Deutsches Krebsforsch Vektor zur Aktivierung des Immunsystems gegen mit Papillomviren bzw. Sequenzen davon assoziierten Zellen
DE19648962C1 (de) 1996-11-26 1998-02-26 Deutsches Krebsforsch Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
FR2766091A1 (fr) 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
US6228368B1 (en) * 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use
US6183746B1 (en) 1997-10-09 2001-02-06 Zycos Inc. Immunogenic peptides from the HPV E7 protein
DE69940774D1 (de) 1998-06-17 2009-06-04 Idm Pharma Inc Hla-bindende peptide und ihre verwendungen

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0073335A1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1328287C (zh) * 2005-12-29 2007-07-25 西安交通大学 Hpv16 l1蛋白模拟肽及其用于制备hpv16诊断试剂和疫苗的用途

Also Published As

Publication number Publication date
CA2375802A1 (fr) 2000-12-07
US6838084B1 (en) 2005-01-04
US20040258708A1 (en) 2004-12-23
WO2000073335A1 (fr) 2000-12-07
DE19925199A1 (de) 2000-12-07
JP2003502027A (ja) 2003-01-21
AU5527500A (en) 2000-12-18

Similar Documents

Publication Publication Date Title
DE69532532T2 (de) Chimerische papillomavirus-ahnliche partikel
DE60132770T2 (de) Chimäre humane papillomavirus (hpv) l1 moleküle und deren verwendungen
DE69835294T2 (de) Methode zur in vitro auseinander- und wiederzusammensetzung von papillomavirus virusähnlichen teilchen (vlps)
EP1728800A1 (fr) Particules semblables au virus du papillome, protéines de fusion et leur procédé de production
JP2007211026A (ja) パピロマウイルス偽ウイルス及びその調製方法
EP1181312A1 (fr) Epitopes cytotoxiques de cellule t de la proteine l1 du papillomavirus et leur application en diagnostic et therapie
EP1370661A2 (fr) Epitopes lymphocytaires t des proteines l1 et e7 de papillomavirus et leur utilisation a des fins de diagnostic et de therapie
DE69933875T2 (de) Protein-verabreichungssystem, das dem menschlichen papillomavirus ähnliche partikel benützt.
DE4447664C2 (de) Fusionsproteine, Verfahren zu deren Herstellung sowie deren Anwendung
WO2002043757A2 (fr) Medicament pour la prophylaxie ou le traitement de tumeurs induites par le virus du papillome humain de type 18
EP1183367B1 (fr) Epitope cytotoxiques des lymphocytes t, de proteine l1 du papillomavirus, et utilisation dans les domaines du diagnostic et de la therapie
EP1064014B1 (fr) Medicament permettant de prevenir ou de traiter les tumeurs a papillomavirus
JPH08512045A (ja) ヒトパピローマウイルスの合成ペプチド
WO2000073790A1 (fr) Systeme de test pour la detection in vitro d'une reaction immunitaire antigene specifique
EP1066321A2 (fr) Formulation contenant une proteine specifique des papillomavirus, sa fabrication et son utilisation
DE19526752A1 (de) Hocheffiziente Bildung von Papillomavirusähnlichen Partikeln
AU717647B2 (en) Chimeric papillomavirus-like particles

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011219

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20051201